Quantum Technology Partners

Magnolia Broadband, Inc. is a fabless semiconductor company based in Englewood, New Jersey, specializing in wireless communications. Founded in 2000, the company has developed and patented Mobile Transmit Diversity (MTD), a beamforming technology that enhances data throughput and coverage for wireless network operators without requiring changes to existing base stations or infrastructure standards. MTD can be implemented as either a chip or a software-only solution, making it versatile for various applications. Magnolia boasts a comprehensive intellectual property portfolio, including 28 issued patents and 24 pending patents in the U.S., alongside additional patents in international markets. The technology significantly increases spectrum utilization by 40%, improves quality of service for voice and data, and offers a proven gain in uplink performance. Moreover, it extends battery life and reduces emissions, allowing for rapid and cost-effective deployment across multi-band standards and protocols.

Vaxart is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its proprietary platform. Its pipeline includes vaccines for norovirus, influenza, RSV, and HPV, with products administered via convenient room-temperature stable tablets.

BiPar Sciences Inc. is a biotechnology company based in Brisbane, California, focused on developing innovative cancer therapies, particularly through the use of PARP inhibitors. Its lead product, BSI-201, is currently undergoing mid-stage clinical trials for advanced breast cancer, ovarian cancer, and other challenging tumors. BiPar's portfolio also includes candidates targeting therapy-resistant cancers and additional drug programs aimed at enhancing the efficacy of chemotherapy. The company has secured approximately $60 million in venture capital funding from various investors and has attracted venture debt to support its initiatives. In April 2009, BiPar Sciences was acquired by the French pharmaceutical company Sanofi-Aventis, indicating its potential significance in the oncology market.

Vaxart is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its proprietary platform. Its pipeline includes vaccines for norovirus, influenza, RSV, and HPV, with products administered via convenient room-temperature stable tablets.

Corium International specializes in the development, manufacture, and commercialization of transdermal and transmucosal drug delivery systems for various therapeutic areas. Its product portfolio includes treatments for hypertension, chronic pain, teeth whitening, osteoporosis, Alzheimer's disease, psychiatric disorders, Parkinson's disease, and motion sickness. The company focuses on enhancing therapeutic profiles and improving patient outcomes through its proprietary technologies.

StrataGent Life Sciences, Inc. is a specialty drug therapy company focused on developing painless and non-invasive delivery methods for therapeutic treatments that typically require injection. The company's innovative approach utilizes proprietary microjet technology to administer both large and small therapeutic molecules without the need for any device to penetrate the skin. This method aims to enhance patient comfort and adherence to treatment protocols. In recognition of its pioneering work, StrataGent received a $2 million award from the Advanced Technology Program at the National Institute of Standards and Technology in May 2004 to further advance its microjet technology.

BiPar Sciences Inc. is a biotechnology company based in Brisbane, California, focused on developing innovative cancer therapies, particularly through the use of PARP inhibitors. Its lead product, BSI-201, is currently undergoing mid-stage clinical trials for advanced breast cancer, ovarian cancer, and other challenging tumors. BiPar's portfolio also includes candidates targeting therapy-resistant cancers and additional drug programs aimed at enhancing the efficacy of chemotherapy. The company has secured approximately $60 million in venture capital funding from various investors and has attracted venture debt to support its initiatives. In April 2009, BiPar Sciences was acquired by the French pharmaceutical company Sanofi-Aventis, indicating its potential significance in the oncology market.

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

Magnolia Broadband, Inc. is a fabless semiconductor company based in Englewood, New Jersey, specializing in wireless communications. Founded in 2000, the company has developed and patented Mobile Transmit Diversity (MTD), a beamforming technology that enhances data throughput and coverage for wireless network operators without requiring changes to existing base stations or infrastructure standards. MTD can be implemented as either a chip or a software-only solution, making it versatile for various applications. Magnolia boasts a comprehensive intellectual property portfolio, including 28 issued patents and 24 pending patents in the U.S., alongside additional patents in international markets. The technology significantly increases spectrum utilization by 40%, improves quality of service for voice and data, and offers a proven gain in uplink performance. Moreover, it extends battery life and reduces emissions, allowing for rapid and cost-effective deployment across multi-band standards and protocols.

BiPar Sciences Inc. is a biotechnology company based in Brisbane, California, focused on developing innovative cancer therapies, particularly through the use of PARP inhibitors. Its lead product, BSI-201, is currently undergoing mid-stage clinical trials for advanced breast cancer, ovarian cancer, and other challenging tumors. BiPar's portfolio also includes candidates targeting therapy-resistant cancers and additional drug programs aimed at enhancing the efficacy of chemotherapy. The company has secured approximately $60 million in venture capital funding from various investors and has attracted venture debt to support its initiatives. In April 2009, BiPar Sciences was acquired by the French pharmaceutical company Sanofi-Aventis, indicating its potential significance in the oncology market.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.

The company develops code division multiple access chipsets for wireless voice and data products.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.